ORI Capital

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

AffyImmune Therapeutics is a biopharmaceutical company focused on advancing Chimeric Antigen Receptor (CAR) T cell therapy specifically for solid tumors. The company develops genetically engineered immune cells aimed at enhancing the safety and effectiveness of cell-based immunotherapy for cancer. Utilizing a proprietary technology, AffyImmune tunes the affinity of CAR-T therapies from picomolar to micromolar levels, which is designed to reduce on-target off-tumor toxicity and broaden the applicability of these treatments to solid tumors. This innovative approach seeks to provide a more effective therapeutic option for patients suffering from various carcinogenic diseases.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

Pillar Biosciences develops next-generation sequencing based assays and software for NGS laboratories. It offers SLIMamp, a Stem-Loop Inhibition-Mediated amplification technology that enables specific priming of overlapping target segments, and PiVAT, an integrated bioinformatics analysis pipeline that produces an enhanced PBAM file for improved local realignment and read assembly. Founded in 2014, the company is headquartered in Natick, Massachusetts, with a presence in Shanghai, China. Its platform focuses on targeted sequencing to support treatment decisions in oncology, delivering high sensitivity and specificity for clinical samples. Pillar has released targeted panels such as Lung and Colon Cancer Somatic Mutation Panel and BRCA1/BRCA2 germline panels for validation by cancer centers and clinical testing companies in the US and China. The company emphasizes faster data delivery, lower costs, and broader access to localized diagnostics through its proprietary technology.

CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.

Enable Injections designs and manufactures wearable devices that deliver injectable drugs directly into the subcutaneous tissue. The system accepts standard vials, syringes, or cartridges, automatically reconstitutes lyophilized solutions, warms the drug, and injects high‑viscosity or high‑volume payloads up to 20 ml. Users place the device on the skin, press a central button, and monitor delivery progress through a viewing window before disposing of the single‑use injector. The company also offers transfer systems for partial or multi‑vial filling and a Bluetooth‑enabled version that can connect to smartphones. Founded in 2010, the company is headquartered in Cincinnati, Ohio, and targets a growing market for self‑administration of biologics and other therapeutics.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

TriSalus Life Sciences is a biotechnology company based in Westminster, Colorado, founded in 2009. The company specializes in developing innovative precision infusion systems for the interventional radiology market, focusing on the treatment of liver and pancreatic cancers. TriSalus's flagship products include the Surefire precision infusion systems, which utilize a unique expandable tip design to deliver embolic agents precisely while minimizing damage to healthy tissue. The company also offers Pressure Enabled Drug Delivery (PEDD) systems and is developing an investigational agent, nelitolimod, aimed at enhancing immune responses in cancer therapies. Additionally, TriSalus is advancing its TriNav therapy delivery device, which incorporates SmartValve technology for improved drug delivery.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

Enable Injections designs and manufactures wearable devices that deliver injectable drugs directly into the subcutaneous tissue. The system accepts standard vials, syringes, or cartridges, automatically reconstitutes lyophilized solutions, warms the drug, and injects high‑viscosity or high‑volume payloads up to 20 ml. Users place the device on the skin, press a central button, and monitor delivery progress through a viewing window before disposing of the single‑use injector. The company also offers transfer systems for partial or multi‑vial filling and a Bluetooth‑enabled version that can connect to smartphones. Founded in 2010, the company is headquartered in Cincinnati, Ohio, and targets a growing market for self‑administration of biologics and other therapeutics.

Pillar Biosciences develops next-generation sequencing based assays and software for NGS laboratories. It offers SLIMamp, a Stem-Loop Inhibition-Mediated amplification technology that enables specific priming of overlapping target segments, and PiVAT, an integrated bioinformatics analysis pipeline that produces an enhanced PBAM file for improved local realignment and read assembly. Founded in 2014, the company is headquartered in Natick, Massachusetts, with a presence in Shanghai, China. Its platform focuses on targeted sequencing to support treatment decisions in oncology, delivering high sensitivity and specificity for clinical samples. Pillar has released targeted panels such as Lung and Colon Cancer Somatic Mutation Panel and BRCA1/BRCA2 germline panels for validation by cancer centers and clinical testing companies in the US and China. The company emphasizes faster data delivery, lower costs, and broader access to localized diagnostics through its proprietary technology.